A Phase 4 interventional study of Gentamycin with Platform Wound Device in Wounds and Injury, Burn Wound and Infection Wound, sponsored by The Metis Foundation. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-14.
Sponsored by The Metis Foundation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.
Among the 336 studies in Burns with a site in United States, this one is the 77th largest by enrollment of the 272 interventional ones that give a count, is one of 16 that started in 2021, is one of 25 in phase 4, and was the 262nd registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:
Jason Sperry · Sites in United States
Ages 18–75
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 18–80
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 18–80
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
336 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 30 · Phase 4 25
First in 1992; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 26 across the 272 interventional studies, 59 across the 61 observational. Of the 226 that completed or were terminated, 74 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 336 have an industry lead sponsor. The 10 most frequent:
The Metis Foundation is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
The Metis Foundation has 8 studies filed under Burns — fewer than ten, so there is no comparison to draw.
10 of the studies in Burns with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05223998The Metis FoundationManual Implantation of Full-Thickness Skin Microcolumns | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT05462860The Metis FoundationSuprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds | 2026-12-09 |
| NCT01297400Skingenix, Inc.Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns | 2026-12-31 |
| NCT07221903University of WashingtonThe Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 336 studies in Burns with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of a novel Platform Wound Device (PWD) in its delivery of a local antibiotic, 0.1% Gentamycin cream, to prevent or treat infection in torso and extremity wounds. The hypothesis is that the PWD will be a safe and effective method to provide topical antibiotics to a torso or extremity wound, non-inferior to the current standard of care. This treatment will reduce or rapidly eradicate infection.
This is a prospective, randomized, controlled clinical trial comparing the use of a platform wound device as compared to standard of care to prevent or eliminate infection in torso and extremity wounds. Patients 18-85 years of age admitted for treatment of open wound(s) will be screened for inclusion criteria and asked to consent to participate in the randomized study. The first 10 patients will be treated with the PWD + gentamicin and will serve as a safety subset. Baseline measurement of serum antibiotic concentraion will be taken prior to PWD placement and one day after. Following the safety subset, 50 patients will be randomized to standard of care or to a single application of the PWD + gentamicin. Baseline assessments will be completed on day 0, including screening, pre-procedure wound evaluation, imaging, assessments, and specimen collection. Follow-up assessments will be completed and data gathered at days 1,2,3 and 4. All data collected of the study participants will be used to evaluate the PWD delivery of antibiotic.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
This study's enrollment of 48 is above the median of 40 across 664 interventional studies indexed under Burns.
Browse Burns studies →The Metis Foundation is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Compared within Burns, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Wounds and Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.
Combination Product: Gentamycin with Platform Wound Device
Study wounds will be treated per the standard of care.
Treatment of wounds with gentamycin and covered with platform wound device.
Feasibility of treatment
Demonstration of the ability to enroll patients at a single institution to either the control group, receiving standard of care, or the treatment group, receiving PWD delivery and 1 dose of antibiotic (0.1% gentamicin cream) over 48 to 96 hours.
Time frame: 48 to 96 hours
Tolerability of treatment
To demonstrate that patients are able to tolerate application of the PWD with 0.1% gentamicin cream application. Tolerability will be assessed by documentation of adverse events.
Time frame: 48 to 96 hours
Effectiveness of wound swabs
To demonstrate that wound swabs are an accurate and reliable measurement of infection based on semi-quantitative wound culture results.
Time frame: 48 to 96 hours
Ran from Feb 2021 to primary completion in Nov 2021, 9 months.
Of 21 phase 4 interventional studies under Burns, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 43. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Metis Foundation